Amy E. DeZern

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 537 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes

David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Journal of Clinical Oncology · 2021 · 460 citations · Full text

Medicine, Oncology, Pharmacology +5

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel et al. · Blood · 2015 · 300 citations · Full text

Medicine, Hematology, Immunology +14

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali et al. · Journal of the National Comprehensive Cancer Network · 2016 · 296 citations

Medicine, Hematology, Oncology +17

Diagnostic utility of telomere length testing in a hospital-based setting

Jonathan K. Alder, Vidya Sagar Hanumanthu, Margaret A. Strong et al. · Proceedings of the National Academy of Sciences · 2018 · 281 citations · Full text

Medicine, Genetics, Hematopathology +16